Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics.
Aged
Anti-Bacterial Agents
/ therapeutic use
Biomarkers
/ analysis
Carbapenems
/ therapeutic use
Cephalosporins
/ therapeutic use
Clostridioides difficile
/ drug effects
Clostridium Infections
/ drug therapy
Drug Therapy, Combination
Female
Fluoroquinolones
/ therapeutic use
Follow-Up Studies
Gastrointestinal Microbiome
Hospitalization
Humans
Incidence
Male
Middle Aged
Penicillins
/ therapeutic use
Prospective Studies
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
14 04 2021
14 04 2021
Historique:
received:
11
06
2020
accepted:
03
03
2021
entrez:
15
4
2021
pubmed:
16
4
2021
medline:
12
5
2021
Statut:
epublish
Résumé
Trial enrichment using gut microbiota derived biomarkers by high-risk individuals can improve the feasibility of randomized controlled trials for prevention of Clostridioides difficile infection (CDI). Here, we report in a prospective observational cohort study the incidence of CDI and assess potential clinical characteristics and biomarkers to predict CDI in 1,007 patients ≥ 50 years receiving newly initiated antibiotic treatment with penicillins plus a beta-lactamase inhibitor, 3
Identifiants
pubmed: 33854064
doi: 10.1038/s41467-021-22269-y
pii: 10.1038/s41467-021-22269-y
pmc: PMC8046770
doi:
Substances chimiques
Anti-Bacterial Agents
0
Biomarkers
0
Carbapenems
0
Cephalosporins
0
Fluoroquinolones
0
Penicillins
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2240Investigateurs
Annemarie M S Engbers
(AMS)
Marieke J A de Regt
(MJA)
Herman Goossens
(H)
Basil Britto Xavier
(BB)
Marie-Noelle Bouverne
(MN)
Pieter Monsieurs
(P)
Uta Merle
(U)
Andreas Stallmach
(A)
Jan Rupp
(J)
Johannes Bogner
(J)
Christoph Lübbert
(C)
Gerda Silling
(G)
Oliver Witzke
(O)
Achilleas Gikas
(A)
George Daikos
(G)
Sotirios Tsiodras
(S)
Athanasios Skoutelis
(A)
Helen Sambatakou
(H)
Miquel Pujol
(M)
Jose M Aguado
(JM)
Emilio Bouza
(E)
Javier Cobo
(J)
Benito Almirante
(B)
Simin A Florescu
(SA)
Andrei Vata
(A)
Adriana Hristea
(A)
Mihaela Lupse
(M)
Deborah Postil
(D)
Jean-Michel Molina
(JM)
Victoire De Lastours
(V)
Thomas Guimard
(T)
Jean-Philippe Talarmin
(JP)
Xavier Duval
(X)
Odile Launay
(O)
Références
J Infect Dis. 2018 Jan 30;217(4):628-636
pubmed: 29186529
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Clin Microbiol Infect. 2016 Aug;22 Suppl 4:S63-81
pubmed: 27460910
J Antimicrob Chemother. 2017 Apr 1;72(4):1193-1201
pubmed: 27999064
Eur J Clin Microbiol Infect Dis. 2014 Mar;33(3):377-83
pubmed: 24048726
Am J Gastroenterol. 2015 Mar;110(3):381-90; quiz 391
pubmed: 25732416
FEMS Microbiol Ecol. 2017 Apr 1;93(4):
pubmed: 28334218
Microbiome. 2013 Jun 28;1(1):18
pubmed: 24450844
J Clin Microbiol. 2013 Sep;51(9):2884-92
pubmed: 23804381
Blood. 2015 Oct 1;126(14):1723-8
pubmed: 26209659
N Engl J Med. 2015 Feb 26;372(9):825-34
pubmed: 25714160
Vaccine. 2016 May 17;34(23):2585-92
pubmed: 27079932
Lancet. 2013 Oct 12;382(9900):1249-57
pubmed: 23932219
Clin Microbiol Infect. 2019 Sep;25(9):1127-1132
pubmed: 30771530
Lancet Infect Dis. 2019 May;19(5):487-496
pubmed: 30885591
Clin Infect Dis. 2018 Apr 17;66(9):1326-1332
pubmed: 29360950
Eur J Intern Med. 2018 Apr;50:28-32
pubmed: 29428498
J Clin Microbiol. 2018 Jun 25;56(7):
pubmed: 29720433
Microbiome. 2016 Mar 14;4:12
pubmed: 26975510
J Glob Health. 2017 Jun;7(1):010417
pubmed: 28607673
Clin Microbiol Infect. 2015 Aug;21(8):786.e1-8
pubmed: 25889357
Med Mal Infect. 2018 Feb;48(1):23-29
pubmed: 29336929
Infect Control Hosp Epidemiol. 2018 Jul;39(7):771-781
pubmed: 29695312
Gut Microbes. 2019;10(2):133-141
pubmed: 30118620
Nature. 2015 Jan 8;517(7533):205-8
pubmed: 25337874